Polypeptide cleavage method using OmpT protease variant

US9657323B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9657323-B2
Application numberUS-57382104-A
CountryUS
Kind codeB2
Filing dateSep 29, 2004
Priority dateSep 30, 2003
Publication dateMay 23, 2017
Grant dateMay 23, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A polypeptide cleavage method characterized in that arginine or lysine is at the P1 position of a desired cleavage site in a polypeptide, an amino acid other than aspartic acid, glutamic acid or proline is at the P1′ position, a single basic amino acid or two or three consecutive basic amino acids are situated at any site in the amino acid sequence from the P10 position to the P3 position or from the P3′ position to the P5′ position (with the proviso that a single basic amino acid is not situated at the P6 or P4 position), and OmpT protease or its variant enzyme having a substitution at the 97th amino acid from the N-terminus is used to cleave the desired cleavage site in the polypeptide.

First claim

Opening claim text (preview).

What is claimed is: 1. A process for cleaving a polypeptide comprising cleaving the polypeptide with an E. coli OmpT protease variant consisting of an amino acid substitution at the 97th position of the amino acid sequence of SEQ ID NO: 41, wherein the 97th amino acid from the N-terminus of the E. coli OmpT protease variant is leucine, methionine, or histidine, wherein the polypeptide comprises a cleavage site that is a peptide bond between the P1 position and the P1′ position, and wherein the P1 position is arginine or lysine and the P1′ position is: (1) serine or alanine when the 97th amino acid from the N-terminus of the E. coli OmpT protease variant is leucine; (2) phenylalanine, alanine, serine, cysteine, or tyrosine when the 97th amino acid from the N-terminus of the E. coli OmpT protease variant is methionine; or (3) alanine, valine, isoleucine, methionine, serine, threonine, cysteine, or asparagine when the 97th amino acid from the N-terminus of the E. coli OmpT protease variant is histidine. 2. The process of claim 1 , wherein the amino acid sequence from the P10 position to the P3 position comprises only a single basic amino acid or only two or three consecutive basic amino acids. 3. The process of claim 2 , wherein the basic amino acids are arginine and/or lysine. 4. The process of claim 3 , wherein the basic amino acids are arginine. 5. The process of claim 1 , wherein the polypeptide is a fusion protein comprising a protecting peptide and a target peptide, wherein the C-terminus of the protecting peptide is the P1 position and the N-terminus of the target peptide is the P1′ position, wherein the fusion protein is produced by expressing a gene encoding the fusion protein in a host cell, and wherein cleavage of the fusion protein liberates the target peptide. 6. The process of claim 5 , wherein a single basic amino acid or two or three consecutive basic amino acids are situated in the amino acid sequence from the P10 position to the P3 position. 7. The process of claim 5 , wherein the E. coli OmpT protease variant is produced by expressing a gene encoding the E. coli OmpT protease variant in said host cell. 8. The process of claim 1 , wherein two or three consecutive basic amino acids are situated between the P10 and P3 positions in the polypeptide. 9. The process of claim 8 , wherein three consecutive basic amino acids are situated between the P5 and P3 positions in the polypeptide. 10. A process for cleaving a polypeptide comprising cleaving the polypeptide with an E. coli OmpT protease variant consisting of an amino acid substitution at the position of the amino acid sequence of SEQ ID NO: 41, wherein the 97th amino acid from the N-terminus of the E. coli OmpT protease variant is leucine, methionine, or histidine, wherein the polypeptide comprises a cleavage site that is a peptide bond between the P1 position and the P1′ position, and wherein the P1 position is arginine or lysine and the P1′ position is: (1) serine or alanine when the 97th amino acid from the N-terminus of the E. coli OmpT protease variant is leucine; (2) phenylalanine, alanine, serine, cysteine, or tyrosine when the 97th amino acid from the N-terminus of the E.coli OmpT protease variant is methionine: or (3) alanine, valine, isoleucine, methionine, serine, threonine, cysteine, or asparagine when the 97th amino acid from the N-terminus of the E. coli OmpT protease variant is histidine, and wherein the amino acid sequence from the P5 to P1 positions in the polypeptide is Arg-Arg-Arg-Ala-Arg (SEQ ID NO: 11). 11. A process for cleaving a polypeptide comprising cleaving the polypeptide with an E. coli OmpT protease variant consisting of an amino acid substitution at the 97the position of the amino acid sequence of SEQ ID NO: 41, wherein the 97th amino acid from the N-terminus of the E. coli OmpT protease variant is leucine, methionine, or histidine, wherein the polypeptide comprises a cleavage site that is a peptide bond between the P1 position and the P1′ position, and wherein the P1′ position is: (1) serine or alanine when the 97th amino acid from the N-terminus of the E. coli OmpT protease variant is leucine; (2) phenylalanine, alanine, serine, cysteine, or tyrosine when the 97th amino acid from the N-terminus of the E. coli OmpT protease variant is methionine; or (3) alanine, valine, isoleucine, methionine, serine threonine, cysteine, or asparagine, when the 97th amino acid from the N-terminus of the E. coli OmpT protease variant is histidine, and wherein the amino acid sequence from the P7 to P1 positions in the polypeptide is Asp-Ala-Arg-Arg-Arg-Ala-Arg (SEQ ID NO: 12). 12. The process of claim 5 , wherein the target peptide consists of between 22 and 45 amino acid residues. 13. The process of claim 12 , wherein the target peptide is adrenocorticotropic hormone (1-24), motilin, or calcitonin precursor.

Assignees

Inventors

Classifications

  • derived from bacteria {or Archaea} · CPC title

  • Corticotropin [ACTH] · CPC title

  • C12P21/06Primary

    produced by the hydrolysis of a peptide bond, e.g. hydrolysate products (preparing foodstuffs by protein hydrolysis A23J3/00) · CPC title

  • Motilins · CPC title

  • Calcitonins · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9657323B2 cover?
A polypeptide cleavage method characterized in that arginine or lysine is at the P1 position of a desired cleavage site in a polypeptide, an amino acid other than aspartic acid, glutamic acid or proline is at the P1′ position, a single basic amino acid or two or three consecutive basic amino acids are situated at any site in the amino acid sequence from the P10 position to the P3 position or fr…
Who is the assignee on this patent?
Okuno Kazuaki, Yabuta Masayuki, Daiichi Sankyo Co Ltd
What technology area does this patent fall under?
Primary CPC classification C12P21/06. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).